European Heart Journal vs Clinical Infectious Diseases: Which Journal Should You Choose?

EHJ asks whether the paper matters across cardiology. CID asks whether the paper changes infectious-disease decision-making.

That's the practical split.

EHJ's editorial guidance emphasize field-wide cardiovascular consequence. CID's editorial guidance emphasize clinically meaningful infectious-disease management, with concrete consequences for diagnosis, treatment, prevention, or stewardship. So a paper can be methodologically excellent and still be clearly one journal's problem more than the other's.

EHJ wins when the manuscript is still fundamentally a cardiology paper.

That usually means:

• cardiovascular outcomes or cardiovascular management are the core consequence
• cardiologists are the primary audience
• the paper changes how cardiovascular disease is interpreted or managed
• the infectious-disease context is important, but not the whole editorial identity

Examples:

• endocarditis or myocarditis papers where the central message is cardiovascular outcomes or cardiovascular management strategy
• device or valve infection studies where the main question is how cardiologists should decide or act
• infection-related cardiovascular-risk studies with broad cardiology relevance

CID wins when the manuscript is still fundamentally an infectious-disease paper.

That includes:

• diagnostic, antimicrobial, or treatment questions
• papers with clear implications for infectious-disease management
• clinically useful cohort or comparative-effectiveness studies in infection
• studies where the real audience is ID physicians, stewardship leaders, or infection specialists

CID's editorial guidance is consistent on this point. The journal is built around clinical consequence in infectious disease, not just interesting pathogen science and not just general medical prestige.

CID's editorial guidance says the journal wants studies that change diagnosis, treatment, prevention, or patient management. Basic microbiology or descriptive infection data without a clear clinical consequence are weak fits.

EHJ's editorial guidance stresses that the work must matter across cardiology, not just inside one specialist infection niche.

This matters because many endocarditis, antimicrobial, or diagnostic papers remain most useful when written in infectious-disease language, even if the cardiovascular stakes are high.

Infection isn't disqualifying. But the manuscript has to become a cardiology paper, not just an ID paper with cardiac outcomes attached.

• the manuscript is fundamentally cardiovascular
• cardiologists are the primary audience
• the paper changes cardiovascular interpretation, outcomes, or management
• the infectious-disease angle matters, but doesn't define the whole paper

That's the EHJ lane.

• the manuscript is fundamentally about infectious-disease management
• ID physicians are the primary audience
• the paper changes diagnosis, treatment, prevention, or stewardship
• cardiovascular findings are important, but still sit inside an ID story

That's the CID lane.

These are classic crossover papers. If the core question is antimicrobial strategy, microbiology, or infection management, CID usually wins. If the core question is surgery timing, hemodynamic consequence, or broad cardiovascular outcomes, EHJ becomes more plausible.

Ask whether the readers who most need the message are cardiologists or infectious-disease physicians. That usually settles it.

These can go either way. If the paper is mostly about device management, extraction decisions, or cardiovascular consequences, EHJ is stronger. If it's mainly about organism profile, antimicrobial treatment, or infection-management strategy, CID is cleaner.

This is a realistic cascade when the manuscript was just framed for the wrong audience.

A paper rejected by EHJ because it's too infection-specific can still do well at CID if:

• the study is clinically actionable
• the infection management message is strong
• the methods support a clinician-facing conclusion

The reverse route is possible, but harder. A paper rejected by CID because it lacks enough clinical ID consequence doesn't become an EHJ paper unless the cardiovascular consequence was actually the main story all along.

If the value of the paper mainly emerges inside infectious-disease practice, EHJ will often look like the wrong venue.

CID's editorial guidance are very clear that clinically thin papers, especially descriptive ones, struggle there.

A cross-specialty title isn't enough. The result must matter across cardiology.

Even a strong methodology section isn't enough if the patient-management consequence is unclear.

A strong EHJ first page tells a cardiology editor why the result changes cardiovascular interpretation or management immediately.

A strong CID first page tells an infectious-disease editor why the result changes diagnosis, treatment, prevention, or management immediately.

If only one of those openings feels natural, that usually tells you the better home.

This pair is unforgiving when the audience is wrong.

An endocarditis paper that's written like an infection-management manuscript can look strangely incomplete to a cardiology editor, even if the data are good. A valve or device paper written like a cardiology outcomes paper can look oddly misframed to an infectious-disease editor if the antimicrobial, diagnostic, or stewardship consequence is the real reason the study matters.

That's why this comparison shouldn't be treated like a prestige ladder. These journals don't mainly sort papers by who is "better." They sort papers by who the paper is actually for.

Try finishing one of these sentences:

• "this changes what cardiologists should do" points toward European Heart Journal
• "this changes how infectious-disease clinicians diagnose or treat patients" points toward Clinical Infectious Diseases

That simple test is often enough to break the tie.

Send to European Heart Journal first if:

1. the manuscript is fundamentally cardiovascular
2. cardiologists are the main audience
3. cardiovascular consequence is the main reason the paper matters
4. infection context is important, but still secondary

Send to Clinical Infectious Diseases first if:

1. the manuscript is fundamentally ID focused
2. ID clinicians are the main audience
3. the practical consequence is in diagnosis, treatment, prevention, or stewardship
4. cardiovascular findings are meaningful, but still inside an infection story

That is also why the safer strategy is usually to write the cover letter for the audience that will understand the claim fastest. If that audience is narrower, you usually shouldn't hide from that. You should submit to the journal that can judge the paper on the right terms the first time.